Biodexa Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Biodexa Pharmaceuticals has been growing earnings at an average annual rate of 12.5%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 25.7% per year.
Key information
12.5%
Earnings growth rate
85.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -25.7% |
| Return on equity | -154.0% |
| Net Margin | -1,543.1% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Biodexa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1 | -8 | 5 | 0 |
| 31 Mar 23 | 1 | -8 | 5 | 0 |
| 31 Dec 22 | 1 | -8 | 5 | 0 |
| 30 Sep 22 | 1 | -7 | 4 | 0 |
| 30 Jun 22 | 1 | -5 | 3 | 0 |
| 31 Mar 22 | 1 | -5 | 3 | 0 |
| 31 Dec 21 | 1 | -5 | 3 | 0 |
| 30 Sep 21 | 1 | -7 | 4 | 0 |
| 30 Jun 21 | 1 | -8 | 3 | 0 |
| 31 Mar 21 | 0 | -15 | 4 | 0 |
| 31 Dec 20 | 0 | -22 | 5 | 0 |
| 30 Jun 20 | 0 | -22 | 5 | 0 |
| 31 Mar 20 | 1 | -16 | 5 | 0 |
| 31 Dec 19 | 1 | -9 | 4 | 0 |
| 30 Jun 19 | 2 | -9 | 4 | 0 |
| 31 Mar 19 | 2 | -10 | 4 | 0 |
| 31 Dec 18 | 2 | -10 | 4 | 0 |
| 30 Jun 18 | 1 | -11 | 4 | 0 |
| 31 Mar 18 | 1 | -11 | 4 | 0 |
| 31 Dec 17 | 1 | -12 | 4 | 0 |
| 30 Sep 17 | -3 | -1 | -7 | -5 |
| 30 Jun 17 | 4 | -18 | 10 | 6 |
| 31 Mar 17 | 6 | -19 | 14 | 7 |
| 31 Dec 16 | 1 | -6 | 3 | 0 |
| 30 Sep 16 | 5 | -17 | 12 | 10 |
| 30 Jun 16 | 4 | -13 | 13 | 6 |
| 31 Mar 16 | 3 | -12 | 9 | 6 |
| 31 Dec 15 | 1 | -10 | 3 | 9 |
| 30 Sep 15 | 1 | -10 | 6 | 5 |
| 30 Jun 15 | 0 | -11 | 7 | 4 |
| 31 Mar 15 | 0 | -10 | 6 | 4 |
| 31 Dec 14 | 0 | -9 | 4 | 4 |
| 30 Sep 14 | 0 | -7 | 4 | 3 |
| 30 Jun 14 | 0 | -5 | 2 | 3 |
| 31 Mar 14 | 0 | -4 | 2 | 3 |
| 31 Dec 13 | 0 | -4 | 2 | 3 |
Quality Earnings: 5MP0 is currently unprofitable.
Growing Profit Margin: 5MP0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5MP0 is unprofitable, but has reduced losses over the past 5 years at a rate of 12.5% per year.
Accelerating Growth: Unable to compare 5MP0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5MP0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 5MP0 has a negative Return on Equity (-154.05%), as it is currently unprofitable.